Key takeaways from the European Society of Gastrointestinal Endoscopy (ESGE) guidelines for the performance matrix in endoscopic ultrasound (EUS): 1. **Informed Patient Consent**: ESGE mandates that informed patient consent must be obtained for 100% of EUS procedures to ensure ethical and legal compliance.
Key takeaways from the European Society of Gastrointestinal Endoscopy (ESGE) guidelines for the performance matrix in endoscopic ultrasound (EUS):
1. **Informed Patient Consent**: ESGE mandates that informed patient consent must be obtained for 100% of EUS procedures to ensure ethical and legal compliance.
2. **Adequate Documentation of Landmarks**: At least 90% of EUS procedures should include detailed documentation of anatomical landmarks to maintain high-quality diagnostic standards.
3. **Structured Training and Supervision**: ESGE recommends structured training programs for EUS trainees, with at least 20% of procedures involving supervised training using assessment tools to ensure competency development.
4. **Standardized Description of Pancreatic Cystic Lesions**: A standardized description of pancreatic cystic lesions should be provided in at least 85% of cases to ensure uniform reporting and clinical decision-making.
5. **Diagnostic Tissue Acquisition**: ESGE emphasizes diagnostic tissue acquisition using EUS-guided fine-needle aspiration (FNA) or fine-needle biopsy (FNB) for solid lesions, with a success rate of ≥85% of procedures.
6. **Adverse Events Monitoring**: Adverse events should be kept below 5% for procedures involving cystic lesions and below 3% for solid lesions, ensuring patient safety.
7. **Updated Antibiotic Use for Cystic Lesions**: The previous recommendation to administer antibiotics for EUS-guided puncture of cystic lesions has been omitted in the current guideline due to recent evidence suggesting it may not be necessary.
8. **Quality Assessment at Center Level**: ESGE emphasizes the importance of monitoring and evaluating EUS performance metrics at both the center and individual endoscopist levels to ensure consistent quality.
9. **Landmark Documentation as a Quality Indicator**: Proper documentation of anatomical landmarks serves as a critical quality indicator for the accuracy and reliability of EUS procedures.
10. **Training and Assessment Tools**: ESGE advocates for the use of structured assessment tools during EUS training to objectively evaluate the skills of trainees and improve their proficiency.
11. **Focus on Pancreatic Lesions**: Special attention is given to standardizing the description and management of pancreatic cystic lesions, reflecting the importance of accurate diagnosis in this area.
12. **Diagnostic Yield Optimization**: The guideline underscores the importance of optimizing diagnostic tissue acquisition using EUS-guided fine-needle techniques to improve diagnostic yield for solid lesions.
13. **Minimizing Adverse Events**: ESGE sets clear benchmarks for minimizing adverse events in EUS procedures to prioritize patient safety and procedural efficacy.
14. **Evidence-Based Updates**: The guideline reflects recent evidence in its recommendations, such as omitting the routine use of antibiotics for puncturing cystic lesions, showcasing ESGE's commitment to evidence-based practice.
15. **Continuous Quality Improvement**: ESGE encourages centers to adopt these performance measures as part of their continuous quality improvement initiatives, ensuring better outcomes for patients undergoing EUS procedures.
These takeaways highlight ESGE's commitment to improving the quality, safety, and effectiveness of endoscopic ultrasound practices across Europe.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.